Universe Pharmaceuticals (NASDAQ:UPC) Shares Up 0.7% – Should You Buy?

Shares of Universe Pharmaceuticals INC (NASDAQ:UPC) were up 0.7% during trading on Wednesday . The company traded as high as $3.00 and last traded at $2.91. 40,949 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 309,696 shares. The stock had previously closed at $2.89.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Universe Pharmaceuticals in a research note on Friday, May 1st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Universe Pharmaceuticals Price Performance

The firm has a fifty day simple moving average of $3.04 and a two-hundred day simple moving average of $3.35.

Universe Pharmaceuticals Company Profile

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.